ProtAffin Biotechnologie AG's technology is based on the interactions between pro-inflammatory proteins such as chemokines, and leucocytes and endothelial cells that drive many acute and chronic inflammatory processes such as ischemia/reperfusion injury and rheumatoid arthritis. The company's CellJammer platform uses structural bioinformatics and rational protein engineering to take a target protein agonist that naturally binds to a GAG ligand and to create an antagonist that binds with higher affinity and blocks the target protein-GAG interaction.
Impulszentrum Graz-West
Reininghausstrasse 13a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.